ClinicalTrials.gg
CompletedNCT01916967Updated Jun 18, 2024Results posted

An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)

A Phase 3 interventional study of Desloratadine and Placebo in Urticaria, sponsored by Organon and Co. Completed. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-06-18.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
239
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing desloratadine in Urticaria — none open to participants now, none under way, none of them phase 3. desloratadine · Urticaria.

Enrollment
2nd of 10
239 · median 139
Started
2013
with 1 other
Phase 3
3 of 10
none open now
Registered
9th of 10
by date
Lead sponsor
6 of 10
Organon and Co

Among the 10 studies testing desloratadine in Urticaria, this one is the 2nd largest by enrollment, is one of 2 that started in 2013, is one of 3 in phase 3, and was the 9th registered.

Urticaria

148 studies on the registry are indexed under Urticaria; 19 are open to participants now.

Browse Urticaria studies →

Open to participants now

None of the 10 studies testing desloratadine in Urticaria is open now. The open studies under Urticaria, anywhere →

Where they have run

About desloratadine

desloratadine: first FDA approval 2001 (CLARINEX), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 12 Urticaria studies recruiting now, 3 (25%) set no upper age limit and 6 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing desloratadine in Urticaria as a file.
02

Study summary

This is a study to evaluate the efficacy and safety of desloratadine (MK-4117) in Japanese participants with chronic urticaria. The primary hypothesis is that the efficacy of desloratadine 10 mg and 5 mg is superior to placebo as based on the change from Baseline in the sum score of pruritus/itch and rash as assessed by the Investigator at Week 2.

03

Conditions studied

  • Urticaria

Keywords

  • Urticaria
  • Skin Diseases, Vascular
  • Skin Diseases
  • Hypersensitivity, Immediate
  • Hypersensitivity
  • Immune System Diseases
  • Cholinergic Antagonists
  • Cholinergic Agents
  • Neurotransmitter Agents
  • Histamine H1 Antagonists, Non-Sedating
  • Histamine H1 Antagonists
  • Histamine Antagonists
  • Histamine Agents
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic urticaria [rash (erythema, wheal) for more than 1 month without any known cause]
  • Out-patient

Exclusion criteria

Exclusion Criteria:

  • Stimulation-induced urticaria [physical urticaria (e.g. cold, solar, and heat urticaria), cholinergic urticaria, contact urticaria)]
  • to antihistamines or ingredients of a study drug
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
239 participants (actual)

Study arms

  • Experimental
    Desloratadine 5 mg

    Participants receive desloratadine 5 mg, as one 5-mg tablet and one placebo tablet, orally, once daily in the evening for 2 weeks

    Drug: Desloratadine · Drug: Placebo

  • Experimental
    Desloratadine 10 mg

    Participants receive desloratadine 10 mg, as two 5-mg tablets, orally, once daily in the evening for 2 weeks

    Drug: Desloratadine

  • Placebo comparator
    Placebo

    Participants receive placebo, as two tablets, orally, once daily in the evening for 2 weeks

    Drug: Placebo

Interventions

  • Desloratadine 5 mg tablets, given orally, once daily in the evening for 2 weeks

  • DrugPlacebo

    Placebo tablets, given orally, once daily in the evening for 2 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Sum Score of Pruritus/Itch and Rash Assessed by Investigator at Week 2

    The Investigator assessed the severity of participant pruritus/itch during the daytime (0=Virtually no itching to 4=Cannot relax because of constant itching) and nighttime (0=Virtually no itching to 4=Cannot sleep because of itching). The score used for pruritus/itch was the higher of the day or night scores (0=Asymptomatic to 4=Severe). The Investigator also assessed the severity of participant rash using the overall rash score (0=No rash to 3=Looks very bad). The sum of the pruritus/itch score (0-4) and rash score (0-3) could range from 0 to 7, with a higher sum score indicating greater severity. The change from Baseline in the sum of the pruritus/itch and overall rash scores at the Week 2 clinic visit was calculated.

    Time frame: Baseline Visit and Week 2 Visit

  2. Number of Participants Who Experienced at Least One Adverse Event (AE)

    An AE is any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study drug, is also an AE.

    Time frame: Up to 4 weeks (Up to 2 weeks after last dose of study drug)

  3. Number of Participants Who Discontinued Study Drug Due to an AE

    An AE is any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study drug, is also an AE.

    Time frame: Up to 2 weeks

Secondary outcomes

  1. Change From Baseline in the Sum Score of Pruritus/Itch and Rash Assessed by Investigator at Day 3 and Week 1

    The Investigator assessed the severity of participant pruritus/itch during the daytime (0=Virtually no itching to 4=Cannot relax because of constant itching) and nighttime (0=Virtually no itching to 4=Cannot sleep because of itching). The score used for pruritus/itch was the higher of the day or night scores (0=Asymptomatic to 4=Severe). The Investigator also assessed the severity of participant rash using the overall rash score (0=No rash to 3=Looks very bad). The sum of the pruritus/itch score (0-4) and rash score (0-3) could range from 0 to 7, with a higher sum score indicating greater severity. The changes from Baseline in the sum of the pruritus/itch and overall rash scores at the Day 3 and Week 1 clinic visits were calculated.

    Time frame: Baseline Visit and Day 3 Visit, Week 1 Visit

  2. Change From Baseline in the Pruritus/Itch Score Assessed by Investigator at Day 3, Week 1 and Week 2

    The Investigator assessed the severity of participant pruritus/itch during the daytime and nighttime (0=Asymptomatic to 4=Severe). The sum of the daytime and nighttime pruritus/itch scores could range from 0 to 8, with a higher score indicating greater severity. The changes from Baseline in the sum of the daytime and nighttime scores at the Day 3, Week 1 and Week 2 clinic visits were calculated.

    Time frame: Baseline Visit and Day 3 Visit, Week 1 Visit, Week 2 Visit

  3. Change From Baseline in the Rash Score Assessed by Investigator at Day 3, Week 1 and Week 2

    The Investigator assessed the severity of participant rash (erythema: 0=no symptom to 3=intensive redness, and wheal: 0=no symptom to 3=significant ridge). The sum score for erythema plus wheal could range from 0 to 6, with a higher score indicating greater severity. The changes from Baseline in the sum score for erythema plus wheal at the Day 3, Week 1 and Week 2 clinic visits were calculated.

    Time frame: Baseline Visit and Day 3 Visit, Week 1 Visit, Week 2 Visit

  4. Number of Participants With a Moderate or Remarkable Improvement in the Global Improvement Rate of Both Pruritus/Itch and Rash (Erythema and Wheal) Assessed by the Investigator at Day 3, Week 1 and Week 2

    The global improvement judgment criteria were used to assess overall improvement in pruritus/itch and rash. The Investigator assessed participant global improvement according to 5 grades (Grade 1=Remarkable improvement to Grade 5=Aggravated). The number of participants with moderate or remarkable improvements was calculated. Remarkable improvement (Grade 1) was defined as both pruritus/itch and rash (erythema and wheal) disappeared, or pruritus/itch disappeared and rash (erythema and wheal) was apparently improved. Moderate improvement (Grade 2) was defined as both pruritus/itch and rash (erythema and wheal) were greatly improved.

    Time frame: Baseline Visit and Day 3 Visit, Week 1 Visit, Week 2 Visit

  5. Change From Baseline in the Pruritus/Itch Score Reported in Participant Diaries at Day 3, Week 1 and Week 2

    Participants assessed the severity of their pruritus/itch during the daytime and nighttime (0=asymptomatic to 4=severe). The sum of the daytime and nighttime pruritus/itch scores could range from 0 to 8, with a higher score indicating greater severity. The changes from Baseline in the sum of the daytime and nighttime scores at the Day 3, Week 1 and Week 2 clinic visits were calculated.

    Time frame: Baseline Visit and Day 3 Visit, Week 1 Visit, Week 2 Visit

  6. Change From Baseline in Pruritus/Itch on a Visual Analog Scale (VAS) Reported by Participants at Day 3, Week 1 and Week 2

    Participants assessed the degree of their pruritus/itching using a 100-mm visual analog scale (VAS) (0 mm=No itch to 100 mm=Worst imaginable itch), with a higher score indicating more severe itching. The changes from Baseline in participant-assessed pruritus/itch at the Day 3, Week 1 and Week 2 clinic visits were calculated.

    Time frame: Baseline Visit and Day 3 Visit, Week 1 Visit, Week 2 Visit

  7. Change From Baseline in the Rash Score Reported in Participant Diaries at Day 3, Week 1 and Week 2

    Participants assessed the severity of their rash (erythema: 0=no symptom to 3=intensive redness, and wheal: 0=no symptom to 3=significant ridge). The sum score for erythema plus wheal could range from 0 to 6, with a higher score indicating greater severity. The changes from Baseline in the sum score for erythema plus wheal at the Day 3, Week 1 and Week 2 clinic visits were calculated.

    Time frame: Baseline Visit and Day 3 Visit, Week 1 Visit, Week 2 Visit

  8. Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score Reported by Participants at Week 1 and Week 2

    The DLQI is a 10-item questionnaire that measures how much participant skin problems have affected their life. Responses to questions about the effect of participant skin problems on life ranged from 0=Not at all to 3=Very much. The DLQI is broken down into 6 subscales: Symptoms and feelings (range 0-6), Daily activities (range 0-6), Leisure (range 0-6), Work and school (range 0-3), Personal relationships (range 0-6), and Treatment (range 0-3). DLQI subscales were summed to yield the DLQI total score, which could range from 0 to 30. For both DLQI subscales and DLQI total score, a higher score indicated a greater negative impact on life. Participants \>=16 years of age completed the DLQI questionnaire about the condition of their skin over the previous week. The changes from Baseline in the DLQI total score at the Week 1 and Week 2 clinic visits were calculated.

    Time frame: Baseline Visit and Week 1 Visit, Week 2 Visit

07

Results

Posted Oct 30, 2014

Participant flow

Participant flow — Overall Study
MilestoneDesloratadine 5 mgDesloratadine 10 mgPlacebo
Started807980
Completed807871
Not completed019
Withdrew: Adverse event002
Withdrew: Lack of efficacy006
Withdrew: Physician decision001
Withdrew: Protocol violation010

Outcome measures

PrimaryChange From Baseline in the Sum Score of Pruritus/Itch and Rash Assessed by Investigator at Week 2

The Investigator assessed the severity of participant pruritus/itch during the daytime (0=Virtually no itching to 4=Cannot relax because of constant itching) and nighttime (0=Virtually no itching to 4=Cannot sleep because of itching). The score used for pruritus/itch was the higher of the day or night scores (0=Asymptomatic to 4=Severe). The Investigator also assessed the severity of participant rash using the overall rash score (0=No rash to 3=Looks very bad). The sum of the pruritus/itch score (0-4) and rash score (0-3) could range from 0 to 7, with a higher sum score indicating greater severity. The change from Baseline in the sum of the pruritus/itch and overall rash scores at the Week 2 clinic visit was calculated.

Time frame:
Baseline Visit and Week 2 Visit
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in the Sum Score of Pruritus/Itch and Rash Assessed by Investigator at Week 2
Score on a ScaleDesloratadine 5 mgDesloratadine 10 mgPlacebo
Change From Baseline in the Sum Score of Pruritus/Itch and Rash Assessed by Investigator at Week 2-3.19 (-3.56 to -2.83)-3.16 (-3.52 to -2.79)-2.02 (-2.40 to -1.65)
Statistical analysis
  • Desloratadine 5 mg vs Placebo · Constrained Longitudinal Data Analysis · p = <0.001 · Difference in ls means: -1.17 · 95% CI -1.69 to -0.65Model with terms of visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable
  • Desloratadine 10 mg vs Placebo · Constrained Longitudinal Data Analysis · p = <0.001 · Difference in ls means: -1.13 · 95% CI -1.66 to -0.61Model with terms of visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable
PrimaryNumber of Participants Who Experienced at Least One Adverse Event (AE)

An AE is any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study drug, is also an AE.

Time frame:
Up to 4 weeks (Up to 2 weeks after last dose of study drug)
Reported as:
Number · Participants
Number of Participants Who Experienced at Least One Adverse Event (AE)
ParticipantsDesloratadine 5 mgDesloratadine 10 mgPlaceboDesloratadine 5 mg→Placebo
Number of Participants Who Experienced at Least One Adverse Event (AE)2418160
PrimaryNumber of Participants Who Discontinued Study Drug Due to an AE

An AE is any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study drug, is also an AE.

Time frame:
Up to 2 weeks
Reported as:
Number · Participants
Number of Participants Who Discontinued Study Drug Due to an AE
ParticipantsDesloratadine 5 mgDesloratadine 10 mgPlaceboDesloratadine 5 mg→Placebo
Number of Participants Who Discontinued Study Drug Due to an AE0020
SecondaryChange From Baseline in the Sum Score of Pruritus/Itch and Rash Assessed by Investigator at Day 3 and Week 1

The Investigator assessed the severity of participant pruritus/itch during the daytime (0=Virtually no itching to 4=Cannot relax because of constant itching) and nighttime (0=Virtually no itching to 4=Cannot sleep because of itching). The score used for pruritus/itch was the higher of the day or night scores (0=Asymptomatic to 4=Severe). The Investigator also assessed the severity of participant rash using the overall rash score (0=No rash to 3=Looks very bad). The sum of the pruritus/itch score (0-4) and rash score (0-3) could range from 0 to 7, with a higher sum score indicating greater severity. The changes from Baseline in the sum of the pruritus/itch and overall rash scores at the Day 3 and Week 1 clinic visits were calculated.

Time frame:
Baseline Visit and Day 3 Visit, Week 1 Visit
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in the Sum Score of Pruritus/Itch and Rash Assessed by Investigator at Day 3 and Week 1
Score on a ScaleDesloratadine 5 mgDesloratadine 10 mgPlacebo
Change from Baseline at Day 3-2.57 (-2.91 to -2.23)-2.75 (-3.09 to -2.41)-0.80 (-1.14 to -0.46)
Change from Baseline at Week 1-3.01 (-3.34 to -2.68)-3.16 (-3.50 to -2.83)-1.39 (-1.72 to -1.06)
SecondaryChange From Baseline in the Pruritus/Itch Score Assessed by Investigator at Day 3, Week 1 and Week 2

The Investigator assessed the severity of participant pruritus/itch during the daytime and nighttime (0=Asymptomatic to 4=Severe). The sum of the daytime and nighttime pruritus/itch scores could range from 0 to 8, with a higher score indicating greater severity. The changes from Baseline in the sum of the daytime and nighttime scores at the Day 3, Week 1 and Week 2 clinic visits were calculated.

Time frame:
Baseline Visit and Day 3 Visit, Week 1 Visit, Week 2 Visit
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in the Pruritus/Itch Score Assessed by Investigator at Day 3, Week 1 and Week 2
Score on a ScaleDesloratadine 5 mgDesloratadine 10 mgPlacebo
Change from Baseline at Day 3-2.62 (-2.97 to -2.27)-2.72 (-3.07 to -2.37)-0.61 (-0.95 to -0.26)
Change from Baseline at Week 1-2.98 (-3.35 to -2.61)-3.13 (-3.50 to -2.76)-1.38 (-1.75 to -1.01)
Change from Baseline at Week 2-3.17 (-3.56 to -2.77)-3.21 (-3.60 to -2.81)-1.91 (-2.31 to -1.50)
SecondaryChange From Baseline in the Rash Score Assessed by Investigator at Day 3, Week 1 and Week 2

The Investigator assessed the severity of participant rash (erythema: 0=no symptom to 3=intensive redness, and wheal: 0=no symptom to 3=significant ridge). The sum score for erythema plus wheal could range from 0 to 6, with a higher score indicating greater severity. The changes from Baseline in the sum score for erythema plus wheal at the Day 3, Week 1 and Week 2 clinic visits were calculated.

Time frame:
Baseline Visit and Day 3 Visit, Week 1 Visit, Week 2 Visit
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in the Rash Score Assessed by Investigator at Day 3, Week 1 and Week 2
Score on a ScaleDesloratadine 5 mgDesloratadine 10 mgPlacebo
Change from Baseline at Day 3-2.31 (-2.63 to -2.00)-2.61 (-2.93 to -2.29)-0.99 (-1.31 to -0.67)
Change from Baseline at Week 1-2.65 (-2.97 to -2.33)-2.98 (-3.30 to -2.66)-1.44 (-1.76 to -1.12)
Change from Baseline at Week 2-2.94 (-3.28 to -2.61)-2.91 (-3.25 to -2.57)-1.98 (-2.33 to -1.64)
SecondaryNumber of Participants With a Moderate or Remarkable Improvement in the Global Improvement Rate of Both Pruritus/Itch and Rash (Erythema and Wheal) Assessed by the Investigator at Day 3, Week 1 and Week 2

The global improvement judgment criteria were used to assess overall improvement in pruritus/itch and rash. The Investigator assessed participant global improvement according to 5 grades (Grade 1=Remarkable improvement to Grade 5=Aggravated). The number of participants with moderate or remarkable improvements was calculated. Remarkable improvement (Grade 1) was defined as both pruritus/itch and rash (erythema and wheal) disappeared, or pruritus/itch disappeared and rash (erythema and wheal) was apparently improved. Moderate improvement (Grade 2) was defined as both pruritus/itch and rash (erythema and wheal) were greatly improved.

Time frame:
Baseline Visit and Day 3 Visit, Week 1 Visit, Week 2 Visit
Reported as:
Number · Participants
Number of Participants With a Moderate or Remarkable Improvement in the Global Improvement Rate of Both Pruritus/Itch and Rash (Erythema and Wheal) Assessed by the Investigator at Day 3, Week 1 and Week 2
ParticipantsDesloratadine 5 mgDesloratadine 10 mgPlacebo
Day 3545515
Week 1545832
Week 2595338
SecondaryChange From Baseline in the Pruritus/Itch Score Reported in Participant Diaries at Day 3, Week 1 and Week 2

Participants assessed the severity of their pruritus/itch during the daytime and nighttime (0=asymptomatic to 4=severe). The sum of the daytime and nighttime pruritus/itch scores could range from 0 to 8, with a higher score indicating greater severity. The changes from Baseline in the sum of the daytime and nighttime scores at the Day 3, Week 1 and Week 2 clinic visits were calculated.

Time frame:
Baseline Visit and Day 3 Visit, Week 1 Visit, Week 2 Visit
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in the Pruritus/Itch Score Reported in Participant Diaries at Day 3, Week 1 and Week 2
Score on a ScaleDesloratadine 5 mgDesloratadine 10 mgPlacebo
Change from Baseline at Day 3-2.37 (-2.74 to -2.00)-2.73 (-3.10 to -2.36)-0.50 (-0.87 to -0.13)
Change from Baseline at Week 1-2.53 (-2.91 to -2.15)-2.85 (-3.24 to -2.47)-1.27 (-1.65 to -0.88)
Change from Baseline at Week 2-2.85 (-3.30 to -2.41)-2.97 (-3.42 to -2.51)-1.75 (-2.23 to -1.27)
SecondaryChange From Baseline in Pruritus/Itch on a Visual Analog Scale (VAS) Reported by Participants at Day 3, Week 1 and Week 2

Participants assessed the degree of their pruritus/itching using a 100-mm visual analog scale (VAS) (0 mm=No itch to 100 mm=Worst imaginable itch), with a higher score indicating more severe itching. The changes from Baseline in participant-assessed pruritus/itch at the Day 3, Week 1 and Week 2 clinic visits were calculated.

Time frame:
Baseline Visit and Day 3 Visit, Week 1 Visit, Week 2 Visit
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in Pruritus/Itch on a Visual Analog Scale (VAS) Reported by Participants at Day 3, Week 1 and Week 2
Score on a ScaleDesloratadine 5 mgDesloratadine 10 mgPlacebo
Change from Baseline at Day 3-35.94 (-41.91 to -29.97)-39.60 (-45.61 to -33.60)-5.22 (-11.19 to 0.75)
Change from Baseline at Week 1-40.82 (-46.55 to -35.09)-48.82 (-54.60 to -43.03)-15.88 (-21.63 to -10.13)
Change from Baseline at Week 2-45.86 (-51.96 to -39.75)-45.01 (-51.17 to -38.84)-25.24 (-31.52 to -18.97)
SecondaryChange From Baseline in the Rash Score Reported in Participant Diaries at Day 3, Week 1 and Week 2

Participants assessed the severity of their rash (erythema: 0=no symptom to 3=intensive redness, and wheal: 0=no symptom to 3=significant ridge). The sum score for erythema plus wheal could range from 0 to 6, with a higher score indicating greater severity. The changes from Baseline in the sum score for erythema plus wheal at the Day 3, Week 1 and Week 2 clinic visits were calculated.

Time frame:
Baseline Visit and Day 3 Visit, Week 1 Visit, Week 2 Visit
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in the Rash Score Reported in Participant Diaries at Day 3, Week 1 and Week 2
Score on a ScaleDesloratadine 5 mgDesloratadine 10 mgPlacebo
Change from Baseline at Day 3-2.21 (-2.57 to -1.85)-2.31 (-2.67 to -1.94)-0.77 (-1.13 to -0.40)
Change from Baseline at Week 1-2.15 (-2.50 to -1.81)-2.43 (-2.77 to -2.08)-1.17 (-1.52 to -0.83)
Change from Baseline at Week 2-2.51 (-2.88 to -2.13)-2.45 (-2.83 to -2.06)-1.70 (-2.11 to -1.29)
SecondaryChange From Baseline in the Dermatology Life Quality Index (DLQI) Total Score Reported by Participants at Week 1 and Week 2

The DLQI is a 10-item questionnaire that measures how much participant skin problems have affected their life. Responses to questions about the effect of participant skin problems on life ranged from 0=Not at all to 3=Very much. The DLQI is broken down into 6 subscales: Symptoms and feelings (range 0-6), Daily activities (range 0-6), Leisure (range 0-6), Work and school (range 0-3), Personal relationships (range 0-6), and Treatment (range 0-3). DLQI subscales were summed to yield the DLQI total score, which could range from 0 to 30. For both DLQI subscales and DLQI total score, a higher score indicated a greater negative impact on life. Participants \>=16 years of age completed the DLQI questionnaire about the condition of their skin over the previous week. The changes from Baseline in the DLQI total score at the Week 1 and Week 2 clinic visits were calculated.

Time frame:
Baseline Visit and Week 1 Visit, Week 2 Visit
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score Reported by Participants at Week 1 and Week 2
Score on a ScaleDesloratadine 5 mgDesloratadine 10 mgPlacebo
Change from Baseline at Week 1-3.82 (-4.52 to -3.12)-4.08 (-4.78 to -3.37)-1.60 (-2.31 to -0.89)
Change from Baseline at Week 2-4.10 (-4.83 to -3.38)-4.01 (-4.74 to -3.28)-2.53 (-3.28 to -1.78)

Adverse events

Collected over Up to 4 weeks (Up to 2 weeks after last dose of study drug). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Desloratadine 5 mg—0/80 (0%)10/80 (12.5%)
Desloratadine 10 mg—0/79 (0%)8/79 (10.1%)
Placebo—0/79 (0%)5/79 (6.3%)
Desloratadine 5 mg→Placebo—0/1 (0%)0/1 (0%)
Most frequent other events
Most frequent other events
EventDesloratadine 5 mgDesloratadine 10 mgPlaceboDesloratadine 5 mg→Placebo
NasopharyngitisInfections and infestations8/803/792/790/1
SomnolenceNervous system disorders3/805/793/790/1

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Desloratadine 5 mgDesloratadine 10 mgPlaceboTotal
Mean38.4 ± 16.340.6 ± 15.839.3 ± 15.239.4 ± 15.7
Sex: Female, Male
Sex: Female, Male(Participants)Desloratadine 5 mgDesloratadine 10 mgPlaceboTotal
Female594845152
Male21313587
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Hide M, Maeda Y, Oshima N, Hisada S. A Phase III clinical trial of desloratadine in Japanese subjects with chronic urticaria: A randomized controlled trial. J Clin Therapeut Med. 2016;32(11):891-903.. [in Japanese] https://mol.medicalonline.jp/archive/search?jo=an9cltmd&ye=2016&vo=32&issue=11

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2013 to primary completion in Feb 2014, 6 months.

Results were first posted in Oct 2014, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2013
First posted
Aug 6, 2013
StartActual
Aug 27, 2013
Primary completionActual
Feb 28, 2014
CompletionActual
Mar 13, 2014
Results first posted
Oct 30, 2014
Last update
Jun 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01916967
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Aug 6, 2013
Start date
Aug 27, 2013
Primary completion
Feb 28, 2014
Completion
Mar 13, 2014
Results posted
Oct 30, 2014
Last update
Jun 18, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Desloratadine

Start the discussion